Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Longboard Pharmaceuticals, Inc.
  6. News
  7. Summary
    LBPH   US54300N1037

LONGBOARD PHARMACEUTICALS, INC.

(LBPH)
  Report
Delayed Nasdaq  -  05/13 03:53:07 pm EDT
4.500 USD   -3.23%
05/12Longboard Pharmaceuticals to Participate in Upcoming Investor Events
AQ
05/06Wedbush Cuts Price Target on Longboard Pharmaceuticals to $12 From $14 'on Lower Net Cash;' Outperform Rating Kept
MT
05/05LONGBOARD PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Longboard Pharmaceuticals : Posts Q2 Loss

08/09/2021 | 11:57am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2021
All news about LONGBOARD PHARMACEUTICALS, INC.
05/12Longboard Pharmaceuticals to Participate in Upcoming Investor Events
AQ
05/06Wedbush Cuts Price Target on Longboard Pharmaceuticals to $12 From $14 'on Lower Net Ca..
MT
05/05LONGBOARD PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Cond..
AQ
05/05Longboard Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended Ma..
CI
05/05Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Fina..
AQ
04/27HC Wainwright Initiates Longboard Pharmaceuticals at Buy with $25 Price Target
MT
04/01Longboard Pharmaceuticals to Present Phase 1 Data for LP352 at the American Academy of ..
AQ
03/23Longboard Pharmaceuticals to Participate in Cantor Fitzgerald's Virtual Rare Orphan Dis..
AQ
03/22Longboard Pharmaceuticals to Participate in Maxim Group 2022 Virtual Growth Conference
AQ
03/22Longboard Pharmaceuticals Names Industry Veteran Randall Kaye as CMO
MT
More news
Analyst Recommendations on LONGBOARD PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -40,3 M - -
Net cash 2022 70,0 M - -
P/E ratio 2022 -2,04x
Yield 2022 -
Capitalization 77,5 M 77,5 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 22
Free-Float 53,8%
Chart LONGBOARD PHARMACEUTICALS, INC.
Duration : Period :
Longboard Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONGBOARD PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 4,50 $
Average target price 19,74 $
Spread / Average Target 339%
EPS Revisions
Managers and Directors
Kevin R. Lind President, CEO, Secretary & Director
Brandi L. Roberts Chief Financial Officer
Paul Jai Sekhri Chairman
Randall E. Kaye Chief Medical Officer
Chadwick J. Orevillo Vice President & Head-Operations
Sector and Competitors
1st jan.Capi. (M$)
LONGBOARD PHARMACEUTICALS, INC.-7.79%77
GILEAD SCIENCES, INC.-14.10%78 232
REGENERON PHARMACEUTICALS, INC.2.22%69 552
VERTEX PHARMACEUTICALS12.35%63 100
WUXI APPTEC CO., LTD.-14.92%43 023
BIONTECH SE-38.39%38 601